Last updated: February 22, 2026
What is the drug listed under NDC 00069-4061?
NDC 00069-4061 corresponds to Sabril (Vigabatrin), approved by the FDA for the treatment of infantile spasms and refractory partial seizures.
Key details:
- Manufacturer: Lundbeck (for Sabril)
- Formulation: 500 mg tablets
- Approved indications: Infantile spasms, refractory partial seizures
- Approval date: August 2009 (FDA)
What is the current market landscape?
Market Size
The global anti-epileptic drug (AED) market, in which Vigabatrin participates, was valued at approximately $4.5 billion in 2021, with a compound annual growth rate (CAGR) of approximately 6% from 2022 to 2027.
Within this, Vigabatrin accounts for a niche segment, primarily driven by its specialized indications and usage in pediatric populations.
Competitive Environment
Major competitors include:
- Levetiracetam (Keppra)
- Valproic acid (Depakote)
- Topiramate (Topamax)
- Lamotrigine (Lamictal)
Vigabatrin's unique position as a drug for infantile spasms limits direct competition but places it within a small, high-cost segment.
Market Penetration
Vigabatrin is typically prescribed after initial therapies have failed, limiting its uptake. Approximately 15,000 to 20,000 patients annually in the US are estimated to use Vigabatrin, mainly pediatric patients with treatment-resistant infantile spasms.
Regulatory and Market Access Factors
- Black box warning regarding potential permanent vision loss limits patient eligibility.
- Reimbursement policies impact pricing strategies.
- Use is often restricted to specialized centers.
What are current pricing trends?
Current list prices (as of 2023)
- Units: 500 mg tablets
- Average wholesale price (AWP): approximately $30 per tablet
Pricing comparison
| Parameter |
Value |
| Price per 30-day supply |
~$900 ($30 * 30 days) |
| Estimated average price (retail) |
$800–$900 |
| Medicaid rebate adjusted price |
~$500–$600 (post-rebate) |
Market trends
- Brand name (Sabril) commands a premium versus generics.
- Generic options are limited; Vigabatrin's patent expired in 2020, but post-expiry generic manufacturing has been slow due to manufacturing complexities and safety concerns.
What are projections for future price movements?
Short-term (1-2 years)
- Slight price decrease expected (~5%) due to generic entry.
- Reimbursement pressures and formulary shifts will further impact net prices.
- Supply chain issues may temporarily inflate prices.
Medium-term (3-5 years)
- Price stabilization anticipated as competition stabilizes.
- Potential for formulary restrictions leading to adaptations in pricing.
- Innovation in formulations or delivery methods could command premium pricing.
Long-term (5+ years)
- Possible further price reductions due to increased generic market share.
- Price erosion may occur unless new indications or formulations emerge.
- Licensing agreements in other territories could influence US pricing.
What are key factors influencing the market and pricing?
- Regulatory restrictions: Black box warnings and safety profile limitations.
- Reimbursement policies: Medicaid/Medicare rebate arrangements influence net price.
- Generic competition: Entry after patent expiry typically reduces prices by 30–50%.
- Manufacturing costs: Complexity in producing Vigabatrin affects pricing flexibility.
- Clinical demand shift: Adoption of alternative therapies for infantile spasms.
Summary
NDC 00069-4061 (Vigabatrin) maintains a niche, high-cost position in the AED space. While current prices are around $30 per tablet, with annual costs nearing $900 for daily therapy, market pressure from generics and safety concerns are expected to induce moderate price declines in the coming years.
Key Takeaways
- Vigabatrin holds a primary market position for infantile spasms with limited competitors.
- Patent expiration in 2020 has introduced generics, leading to potential price reductions.
- Safety restrictions and clinical guidelines influence market penetration and pricing strategies.
- Pricing will likely decline modestly over 2–5 years due to increased generic competition.
- Expected total market size for Vigabatrin in the US remains under 20,000 patients annually.
FAQs
1. Will Vigabatrin’s price decrease significantly after generic entry?
Yes. Typically, generic entry reduces brand drug prices by 30–50%. The impact will depend on manufacturing costs, market demand, and reimbursement policies.
2. Are there any new formulations or indications in development for Vigabatrin?
No active FDA-approved new formulations or indications are publicly announced as of 2023. Future research may explore additional uses in refractory epilepsy.
3. How does safety concern impact pricing and market access?
The black box warning for vision loss limits prescribing to specialized centers, reducing market size and enabling premium pricing but constraining broader adoption.
4. What regions show the most growth potential for Vigabatrin?
Europe and emerging markets with expanding epilepsy treatment access may offer growth, but regulatory and safety concerns could vary.
5. How will reimbursement policies affect future prices?
Reimbursement, especially under Medicaid programs, significantly influences net prices. Rebate negotiations or policy changes can accelerate or slow price declines.
References
[1] U.S. Food and Drug Administration. (2009). Sabril (Vigabatrin) Approval Letter. Retrieved from https://www.accessdata.fda.gov
[2] MarketWatch. (2022). Global Anti-Epileptic Drugs Market Size, Share & Trends.
[3] IQVIA. (2022). Pharmaceutical Market Data and Trends.
